Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Cocrystal Pharma Posts $8.9M Net Loss in Q3 2026 Filing

Cocrystal Pharma, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting financial results for both the three and nine months ended on that date.

Shwetambri Chauhan | 16 November 2026

22nd Century Group Q3 2026: Net Loss $9.4M, Shares at 3.2M

22nd Century Group, Inc. filed its quarterly report on Form 10-Q with the SEC covering the period ended September 30, 2026, disclosing a net loss of $9.4 million for the nine months ended on that date and reporting 3,210,207 shares of common stock outstanding …

Aditi Sarkar | 16 November 2026

DSwiss Q3 2026: Net Income Swings Positive to $70,150

DSwiss, Inc. filed its quarterly report on Form 10-Q with the SEC on November 16, 2026, covering the three and nine months ended September 30, 2026, and reporting a return to quarterly net income after a net loss in the same period of 2025.

Anjali Anand | 16 November 2026

Golden Star Resource Corp. Q1 FY2027 Quarterly Results

Golden Star Resource Corp., a Nevada-incorporated mineral exploration stage company, filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 16, 2026.

Shwetambri Chauhan | 16 November 2026

Jaguar Health Q3 2026: Net Loss Narrows, Equity Turns Positive

Jaguar Health, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting a net loss of $5.830 million for the third quarter and a swing from stockholders' deficit to positive stockholders' equity.

Manish Choudhary | 16 November 2026

Family Office of America Posts $97,281 Net Profit for Nine Months Ended Sept 30, 2026

Family Office of America, Inc. filed a Form 10-Q with the SEC on November 16, 2026, covering the quarterly period ended September 30, 2026, reporting its first period of net profitability on a nine-month basis alongside significant growth in total assets.

Aakashdeep | 16 November 2026

Unicycive Therapeutics Q3 2026: Net Loss $21.5M, Cash Rises

Unicycive Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting a nine-month net loss of $21.543 million and total assets of $69.933 million.

Aditi Sarkar | 16 November 2026

Readvantage Corp. Cancels 1.5M Shares in Q1 FY2027

Readvantage Corp. filed its quarterly report on Form 10-Q with the SEC on November 16, 2026, covering the three months ended September 30, 2026, disclosing a net loss of $10,883 and the cancellation of 1,500,000 common shares during the period.

Manish Choudhary | 16 November 2026

Stonebridge Acquisition II Files 10-Q for Q3 2026

Stonebridge Acquisition II Corporation filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 16, 2026, disclosing financial results and balance sheet data for the blank-check company.

Nitish Kishor | 16 November 2026
Support

Hi! How can we help you today?

Loading…